Iron%252525252525252525252525252525252520sucrose

# Iron Sucrose ## Overview Iron sucrose is a parenteral iron complex used for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD). It acts by replenishing iron stores and providing iron for hemoglobin synthesis. ## Primary Indications * Iron deficiency anemia in patients undergoing chronic hemodialysis (in conjunction with erythropoietin). * Iron deficiency anemia in non-dialysis dependent CKD. * Iron deficiency anemia in peritoneal dialysis-dependent CKD. ## Adult Dosing * **Hemodialysis-dependent CKD:** 100 mg administered intravenously (IV) either as a slow injection or infusion during sequential dialysis sessions for a total cumulative dose of 1,000 mg over 10 sessions. * **Non-dialysis-dependent CKD:** 200 mg IV administered as a slow injection on 5 different occasions within a 14-day period. * **Peritoneal dialysis-dependent CKD:** 300 mg via slow IV infusion at weeks 1 and 3 (total 600 mg), followed by 400 mg at week 5. * *Note: Repeat courses may be required if iron deficiency recurs.* ## Pediatric Dosing * **Hemodialysis-dependent CKD (Aged 2 years and older):** 0.5 mg/kg (max 100 mg) administered IV every 2 weeks for 12 weeks. * **Non-dialysis-dependent CKD (Aged 2 years and older):** 0.5 mg/kg (max 100 mg) administered IV every 2 weeks for 12 weeks. * *Note: Efficacy and safety data are limited; verify local institutional protocols as practices vary widely.* ## Dose Adjustments * **Hepatic Impairment:** No specific adjustment required, but use with caution due to the risk of iron overload. * **Renal Impairment:** Dosing is specifically established based on the dialysis status of the patient (indicated above). ## Contraindications * Hypersensitivity to iron sucrose or any component of the formulation. * Evidence of iron overload (hemochromatosis, hemosiderosis). * Anemia not caused by iron deficiency. ## Adverse Effects * **Common:** Hypotension, dysgeusia (metallic taste), nausea, muscle cramps, injection site reaction. * **Serious:** Anaphylaxis/hypersensitivity reactions (can occur even with prior uneventful doses), iron overload, hypertension. ## Key Drug Interactions * **Oral Iron:** Parenteral iron may reduce the absorption of oral iron preparations. Discontinue oral iron before starting iron sucrose. * **DMSA (Dimercaptosuccinic acid):** Potential to interfere with iron metabolism; avoid concomitant use. ## Monitoring * **Hypersensitivity:** Monitor for signs of anaphylaxis during and for at least 30 minutes following administration. * **Laboratory:** Monitor hemoglobin (Hgb), hematocrit (Hct), serum ferritin, and transferrin saturation (TSAT) to assess response and prevent iron toxicity. * **Vital Signs:** Monitor blood pressure during administration. ## Clinical Pearls * **Administration:** Can be given as a slow IV push (usually over 2–5 minutes) or diluted in 0.9% NaCl and infused over 15–60 minutes depending on dose and clinical setting. * **Hypotension:** Rapid administration is strongly associated with hypotension; avoid exceeding recommended infusion rates. * **Extravasation:** Ensure proper venous access to avoid skin discoloration or irritation at the injection site. * **Documentation:** Always verify the patient's most recent iron studies (Ferritin/TSAT) before initiating iron therapy to confirm the need for repletion. *** *Disclaimer: This information is for educational purposes only. Always consult your institutional formulary, local clinical guidelines, and the most current manufacturer-provided prescribing information before administering any medication.*